Postdoctoral Position in Computational / Functional Genomics

Organization
National Institutes of Health (NIH)
Job Location
Job Description

A postdoctoral position is available in the research group of Dr. Ivan Ovcharenko at the National Institutes of Health (NIH). Our current research projects include computational studies of epigenetic and sequence-based mechanisms of gene regulation. We are developing computational approaches to decipher the regulatory landscape of the human genome. By combining next generation sequencing data with a large body of experimental enhancer characterization, our computational approaches target transcriptional mechanisms of tissue-specific regulatory signals and cell-type differences in gene regulation.

Candidates with a PhD in Computational Biology, Statistics, Population Genetics or a related field, and less than 5 years of prior postdoctoral training are encouraged to apply. Advanced programming and genome data analysis skills are desirable.

Sample publications from the lab:
L. Taher et al., Sequence signatures extracted from proximal promoters can be used to predict distal enhancers, Genome Biology, http://genomebiology.com/content/14/10/R117
R.P. Smith et al., Massively parallel decoding of mammalian regulatory sequences supports a flexible organizational model, Nat Genet., http://www.nature.com/ng/journal/v45/n9/full/ng.2713.html

Stable, multi-year funding, outstanding benefits and compensation. 

If interested, please email your CV and the names of 3 references to Ivan Ovcharenko at ovcharen@nih.gov

How to Apply

please email your CV and the names of 3 references to ovcharen@nih.gov

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.

Gladys Kong writes at Fortune that her STEM background has helped her as a CEO.